Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:

• Introduction (0:00)
• Overview of Prostate Cancer (3:00)
• Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)
• Potential Role of Capivasertib in Metastatic HSPC (27:22)
• Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)
• Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)

CME information and select publications

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics:

• Introduction (0:00)
• Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29)
• Recent Advances in Up-Front Treatment for Metastatic PAD (15:47)
• Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58)
• Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20)
• Utility of Tumor Treating Fields in PAD Management (1:13:58)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:

• Introduction (0:00)
• Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
• Practical Considerations with Oral SERDs (15:43)
• Potential Role of Combination Approaches with Oral SERDs (26:33)
• Gastrointestinal Adverse Events Documented with Oral SERDs (38:19)
• Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54)
• Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56)
• Emerging Utility of Adjuvant Oral SERDs (1:10:20)
• Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22)

CME information and select publications